<!DOCTYPE html>
<html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<meta charset="utf-8">
<meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<title>Myeloproliferative | Hematology</title>
<meta name="author" content="Brett M. Rice">
<meta name="description" content="Overview of Myeloproliferative Neoplasms (MPNs)  Definition: A group of clonal hematopoietic stem cell disorders characterized by increased proliferation of one or more myeloid cell lines in the...">
<meta name="generator" content="bookdown 0.42 with bs4_book()">
<meta property="og:title" content="Myeloproliferative | Hematology">
<meta property="og:type" content="book">
<meta property="og:description" content="Overview of Myeloproliferative Neoplasms (MPNs)  Definition: A group of clonal hematopoietic stem cell disorders characterized by increased proliferation of one or more myeloid cell lines in the...">
<meta name="twitter:card" content="summary">
<meta name="twitter:title" content="Myeloproliferative | Hematology">
<meta name="twitter:description" content="Overview of Myeloproliferative Neoplasms (MPNs)  Definition: A group of clonal hematopoietic stem cell disorders characterized by increased proliferation of one or more myeloid cell lines in the...">
<!-- JS --><script src="https://cdnjs.cloudflare.com/ajax/libs/clipboard.js/2.0.6/clipboard.min.js" integrity="sha256-inc5kl9MA1hkeYUt+EC3BhlIgyp/2jDIyBLS6k3UxPI=" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/fuse.js/6.4.6/fuse.js" integrity="sha512-zv6Ywkjyktsohkbp9bb45V6tEMoWhzFzXis+LrMehmJZZSys19Yxf1dopHx7WzIKxr5tK2dVcYmaCk2uqdjF4A==" crossorigin="anonymous"></script><script src="https://kit.fontawesome.com/6ecbd6c532.js" crossorigin="anonymous"></script><script src="libs/jquery-3.6.0/jquery-3.6.0.min.js"></script><meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
<link href="libs/bootstrap-4.6.0/bootstrap.min.css" rel="stylesheet">
<script src="libs/bootstrap-4.6.0/bootstrap.bundle.min.js"></script><script src="libs/bs3compat-0.9.0/transition.js"></script><script src="libs/bs3compat-0.9.0/tabs.js"></script><script src="libs/bs3compat-0.9.0/bs3compat.js"></script><link href="libs/bs4_book-1.0.0/bs4_book.css" rel="stylesheet">
<script src="libs/bs4_book-1.0.0/bs4_book.js"></script><meta name="google-adsense-account" content="ca-pub-1344282930858290">
<script async src="https://www.googletagmanager.com/gtag/js?id=G-JERRQQFPF4"></script><script>
      window.dataLayer = window.dataLayer || [];
      function gtag(){dataLayer.push(arguments);}
      gtag('js', new Date());

      gtag('config', 'G-JERRQQFPF4');
    </script><script src="https://cdnjs.cloudflare.com/ajax/libs/autocomplete.js/0.38.0/autocomplete.jquery.min.js" integrity="sha512-GU9ayf+66Xx2TmpxqJpliWbT5PiGYxpaG8rfnBEk1LL8l1KGkRShhngwdXK1UgqhAzWpZHSiYPc09/NwDQIGyg==" crossorigin="anonymous"></script><script src="https://cdnjs.cloudflare.com/ajax/libs/mark.js/8.11.1/mark.min.js" integrity="sha512-5CYOlHXGh6QpOFA/TeTylKLWfB3ftPsde7AnmhuitiTX4K5SqCLBeKro6sPS8ilsz1Q4NRx3v8Ko2IBiszzdww==" crossorigin="anonymous"></script><!-- CSS --><style type="text/css">
    
    div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
  </style>
<link rel="stylesheet" href="style.css">
</head>
<body data-spy="scroll" data-target="#toc">

<div class="container-fluid">
<div class="row">
  <header class="col-sm-12 col-lg-3 sidebar sidebar-book"><a class="sr-only sr-only-focusable" href="#content">Skip to main content</a>

    <div class="d-flex align-items-start justify-content-between">
      <h1>
        <a href="index.html" title="">Hematology</a>
      </h1>
      <button class="btn btn-outline-primary d-lg-none ml-2 mt-1" type="button" data-toggle="collapse" data-target="#main-nav" aria-expanded="true" aria-controls="main-nav"><i class="fas fa-bars"></i><span class="sr-only">Show table of contents</span></button>
    </div>

    <div id="main-nav" class="collapse-lg">
      <form role="search">
        <input id="search" class="form-control" type="search" placeholder="Search" aria-label="Search">
</form>

      <nav aria-label="Table of contents"><h2>Table of contents</h2>
        <ul class="book-toc list-unstyled">
<li><a class="" href="index.html">About</a></li>
<li><a class="" href="ascp-boc.html">ASCP BOC</a></li>
<li><a class="" href="reading-list.html">Reading List</a></li>
<li class="book-part">Erythrocytes</li>
<li><a class="" href="rbc-production.html">RBC Production</a></li>
<li><a class="" href="rbc-function.html">RBC Function</a></li>
<li><a class="" href="rbc-destruction.html">RBC Destruction</a></li>
<li><a class="" href="anemais.html">Anemais</a></li>
<li><a class="" href="microcytic.html">Microcytic</a></li>
<li><a class="" href="iron-deficiency.html">Iron Deficiency</a></li>
<li><a class="" href="chronic-disease.html">Chronic Disease</a></li>
<li><a class="" href="thalassemias.html">Thalassemias</a></li>
<li><a class="" href="sideroblastic.html">Sideroblastic</a></li>
<li><a class="" href="porphyria.html">Porphyria</a></li>
<li><a class="" href="normocytic.html">Normocytic</a></li>
<li><a class="" href="hereditary-hemolytic.html">Hereditary Hemolytic</a></li>
<li><a class="" href="acquired-hemolytic.html">Acquired Hemolytic</a></li>
<li><a class="" href="hypoproliferative.html">Hypoproliferative</a></li>
<li><a class="" href="acute-hemorrhage.html">Acute Hemorrhage</a></li>
<li><a class="" href="macrocytic.html">Macrocytic</a></li>
<li><a class="" href="megaloblastic.html">Megaloblastic</a></li>
<li><a class="" href="nonmegaloblastic.html">Nonmegaloblastic</a></li>
<li><a class="" href="hemoglobinopathies.html">Hemoglobinopathies</a></li>
<li><a class="" href="erythrocytosis.html">Erythrocytosis</a></li>
<li class="book-part">Leukocytes</li>
<li><a class="" href="wbc-production.html">WBC Production</a></li>
<li><a class="" href="wbc-function.html">WBC Function</a></li>
<li><a class="" href="wbc-destruction.html">WBC Destruction</a></li>
<li><a class="" href="benign-disorders.html">Benign Disorders</a></li>
<li><a class="" href="myeloid.html">Myeloid</a></li>
<li><a class="" href="lymphoid.html">Lymphoid</a></li>
<li><a class="" href="myeloid-neoplasia.html">Myeloid Neoplasia</a></li>
<li><a class="" href="aml.html">AML</a></li>
<li><a class="" href="myelodysplastic.html">Myelodysplastic</a></li>
<li><a class="active" href="myeloproliferative.html">Myeloproliferative</a></li>
<li><a class="" href="lymphoid-neoplasia.html">Lymphoid Neoplasia</a></li>
<li><a class="" href="acute-lymphoid.html">Acute Lymphoid</a></li>
<li><a class="" href="chronic-b-cell.html">Chronic B-Cell</a></li>
<li><a class="" href="chronic-t-cell.html">Chronic T-Cell</a></li>
<li><a class="" href="plasma-cell.html">Plasma Cell</a></li>
<li class="book-part">Platelets</li>
<li><a class="" href="plt-production.html">PLT Production</a></li>
<li><a class="" href="plt-function.html">PLT Function</a></li>
<li><a class="" href="plt-destruction.html">PLT Destruction</a></li>
<li><a class="" href="quantitative.html">Quantitative</a></li>
<li><a class="" href="thrombocytopenia-1.html">Thrombocytopenia</a></li>
<li><a class="" href="destruction.html">Destruction</a></li>
<li><a class="" href="production.html">Production</a></li>
<li><a class="" href="pseudo.html">Pseudo</a></li>
<li><a class="" href="thrombocytosis.html">Thrombocytosis</a></li>
<li><a class="" href="qualitative.html">Qualitative</a></li>
<li><a class="" href="von-willebrand.html">von Willebrand</a></li>
<li><a class="" href="bernard-soulier.html">Bernard-Soulier</a></li>
<li><a class="" href="glanzmann.html">Glanzmann</a></li>
<li class="book-part">Laboratory</li>
<li><a class="" href="cell-counts.html">Cell Counts</a></li>
<li><a class="" href="manual.html">Manual</a></li>
<li><a class="" href="automated.html">Automated</a></li>
<li><a class="" href="retics.html">Retics</a></li>
<li><a class="" href="differentials.html">Differentials</a></li>
<li><a class="" href="morphologies.html">Morphologies</a></li>
<li><a class="" href="hemoglobin.html">Hemoglobin</a></li>
<li><a class="" href="quantitative-1.html">Quantitative</a></li>
<li><a class="" href="qualitative-1.html">Qualitative</a></li>
<li><a class="" href="electrophoresis.html">Electrophoresis</a></li>
<li><a class="" href="hplc.html">HPLC</a></li>
<li><a class="" href="sickle-solubility.html">Sickle Solubility</a></li>
<li><a class="" href="hematocrit.html">Hematocrit</a></li>
<li><a class="" href="indices.html">Indices</a></li>
<li><a class="" href="hemolysis.html">Hemolysis</a></li>
<li><a class="" href="special-stains.html">Special Stains</a></li>
<li><a class="" href="other-studies.html">Other Studies</a></li>
<li><a class="" href="esr.html">ESR</a></li>
<li><a class="" href="g6pd.html">G6PD</a></li>
<li><a class="" href="heinz-body.html">Heinz Body</a></li>
<li><a class="" href="flow-cytometry.html">Flow Cytometry</a></li>
<li><a class="" href="leukemia.html">Leukemia</a></li>
<li><a class="" href="lymphoma.html">Lymphoma</a></li>
<li><a class="" href="lymphocyte-subsets.html">Lymphocyte Subsets</a></li>
<li><a class="" href="pnh.html">PNH</a></li>
<li><a class="" href="molecularcytogenetic.html">Molecular/Cytogenetic</a></li>
<li><a class="" href="recurring-abnormalities.html">Recurring Abnormalities</a></li>
<li><a class="" href="bcrabl1.html">BCR/ABL1</a></li>
<li><a class="" href="jak2.html">JAK2</a></li>
<li class="book-part">Hemostasis</li>
<li><a class="" href="coagulation-pathways.html">Coagulation Pathways</a></li>
<li><a class="" href="fibrinolytic-pathways.html">Fibrinolytic Pathways</a></li>
<li><a class="" href="vascular-system.html">Vascular System</a></li>
<li><a class="" href="disorders.html">Disorders</a></li>
<li><a class="" href="factor-deficiencies.html">Factor Deficiencies</a></li>
<li><a class="" href="hereditary.html">Hereditary</a></li>
<li><a class="" href="acquired.html">Acquired</a></li>
<li><a class="" href="inhibitors.html">Inhibitors</a></li>
<li><a class="" href="fibrinolytic.html">Fibrinolytic</a></li>
<li><a class="" href="thrombophilia.html">Thrombophilia</a></li>
<li><a class="" href="dic.html">DIC</a></li>
<li><a class="" href="laboratory.html">Laboratory</a></li>
<li><a class="" href="ptinr.html">PT/INR</a></li>
<li><a class="" href="aptt.html">APTT</a></li>
<li><a class="" href="fibrinogen.html">Fibrinogen</a></li>
<li><a class="" href="d-dimer.html">D-dimer</a></li>
<li><a class="" href="thrombin-time.html">Thrombin Time</a></li>
<li><a class="" href="mixing-studies-1.html">Mixing Studies</a></li>
<li><a class="" href="factor-assays.html">Factor Assays</a></li>
<li><a class="" href="inhibitor-assays.html">Inhibitor Assays</a></li>
<li><a class="" href="von-willebrand-assays.html">von Willebrand Assays</a></li>
<li><a class="" href="platelet-function.html">Platelet Function</a></li>
<li><a class="" href="platelet-aggregation.html">Platelet Aggregation</a></li>
<li><a class="" href="thromboelastography.html">Thromboelastography</a></li>
<li><a class="" href="hypercoagulability.html">Hypercoagulability</a></li>
<li><a class="" href="assays.html">Assays</a></li>
<li><a class="" href="antiphospholipids.html">Antiphospholipids</a></li>
<li><a class="" href="protein-c.html">Protein C</a></li>
<li><a class="" href="protein-s.html">Protein S</a></li>
<li><a class="" href="molecular.html">Molecular</a></li>
<li><a class="" href="fv-leiden.html">FV Leiden</a></li>
<li><a class="" href="pt-20210.html">PT 20210</a></li>
<li><a class="" href="anti-xa.html">Anti-Xa</a></li>
<li><a class="" href="thrombin-inhibitors.html">Thrombin Inhibitors</a></li>
<li><a class="" href="heparin-neutralization.html">Heparin Neutralization</a></li>
</ul>

        <div class="book-extra" style="display:none;">
          <p><a id="book-repo" href="https://github.com/brettmrice/Clinical-Hematology/blob">View book source <i class="fab fa-github"></i></a></p>
        </div>
      </nav>
</div>
  </header><main class="col-sm-12 col-md-9 col-lg-7" id="content"><div id="myeloproliferative" class="section level1 unnumbered">
<h1>Myeloproliferative<a class="anchor" aria-label="anchor" href="#myeloproliferative"><i class="fas fa-link"></i></a>
</h1>
<div id="overview-of-myeloproliferative-neoplasms-mpns" class="section level2 unnumbered">
<h2>
<strong>Overview of Myeloproliferative Neoplasms (MPNs)</strong><a class="anchor" aria-label="anchor" href="#overview-of-myeloproliferative-neoplasms-mpns"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Definition:</strong> A group of clonal hematopoietic stem cell disorders characterized by <em>increased</em> proliferation of one or more myeloid cell lines in the bone marrow</li>
<li>
<strong>Key Features:</strong>
<ul>
<li>Increased Blood Cell Counts: Elevated WBC count, RBC count, and/or platelet count</li>
<li>Extramedullary Hematopoiesis: Hematopoiesis (blood cell production) occurs outside the bone marrow, often in the spleen (leading to splenomegaly) and liver</li>
<li>Risk of Thrombosis and Bleeding: Due to abnormal platelet function and/or elevated blood cell counts</li>
<li>Risk of Transformation: Can progress to myelofibrosis (scarring of the bone marrow) or acute leukemia</li>
</ul>
</li>
<li>
<strong>Diagnostic Hallmark:</strong> MPNs are often characterized by specific genetic mutations that drive the increased proliferation</li>
<li>
<strong>Classification:</strong>
<ul>
<li>Chronic Myeloid Leukemia (CML)</li>
<li>Polycythemia Vera (PV)</li>
<li>Essential Thrombocythemia (ET)</li>
<li>Primary Myelofibrosis (PMF)</li>
<li>Other, rarer MPNs</li>
</ul>
</li>
</ul>
</div>
<div id="chronic-myeloid-leukemia-cml" class="section level2 unnumbered">
<h2>
<strong>Chronic Myeloid Leukemia (CML)</strong><a class="anchor" aria-label="anchor" href="#chronic-myeloid-leukemia-cml"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Definition:</strong> A myeloproliferative neoplasm characterized by the presence of the <em>BCR-ABL1</em> fusion gene, resulting from a reciprocal translocation between chromosomes 9 and 22 (t(9;22)(q34.1;q11.2))</li>
<li>
<strong>Pathophysiology:</strong>
<ul>
<li>
<em>BCR-ABL1 Fusion Gene:</em> The translocation creates the Philadelphia chromosome (Ph chromosome) and results in the fusion of the <em>BCR</em> gene on chromosome 22 with the <em>ABL1</em> gene on chromosome 9</li>
<li>
<em>Constitutive Tyrosine Kinase Activity:</em> The BCR-ABL1 fusion protein has constitutive (always “on”) tyrosine kinase activity, which drives uncontrolled proliferation of myeloid cells</li>
</ul>
</li>
<li>
<strong>Phases of CML:</strong>
<ul>
<li>Chronic Phase (CP):
<ul>
<li>Relatively indolent phase with increased WBC count, but &lt;10% blasts in the bone marrow and peripheral blood</li>
</ul>
</li>
<li>Accelerated Phase (AP):
<ul>
<li>Increasing WBC count, blasts between 10-19% in the bone marrow or peripheral blood, resistance to treatment, new cytogenetic abnormalities</li>
</ul>
</li>
<li>Blast Phase (BP):
<ul>
<li>Transformation to acute leukemia (either myeloid or lymphoid) with ≥20% blasts in the bone marrow or peripheral blood</li>
</ul>
</li>
</ul>
</li>
<li>
<strong>Clinical Features:</strong>
<ul>
<li>Chronic Phase:
<ul>
<li>Often asymptomatic</li>
<li>Fatigue</li>
<li>Splenomegaly</li>
<li>Night sweats</li>
<li>Weight loss</li>
</ul>
</li>
<li>Accelerated Phase and Blast Phase:
<ul>
<li>Worsening symptoms</li>
<li>Fever</li>
<li>Bone pain</li>
<li>Bleeding</li>
<li>Infections</li>
</ul>
</li>
</ul>
</li>
<li>
<strong>Laboratory Findings:</strong>
<ul>
<li>CBC:
<ul>
<li>Elevated WBC count (often &gt; 25 x 10^9/L)</li>
<li>Neutrophilia with a “left shift” (increased band neutrophils, metamyelocytes, and myelocytes)</li>
<li>Basophilia</li>
<li>Eosinophilia</li>
<li>Anemia (variable)</li>
<li>Platelet count: Normal or elevated</li>
</ul>
</li>
<li>Peripheral Blood Smear:
<ul>
<li>Increased granulocytes at various stages of maturation</li>
<li>Basophilia</li>
<li>Small number of blasts (in chronic phase)</li>
<li>Presence of blasts and promyelocytes (in accelerated and blast phases)</li>
</ul>
</li>
<li>Bone Marrow Aspiration and Biopsy:
<ul>
<li>Hypercellular marrow with increased granulopoiesis</li>
<li>Myeloid:erythroid (M:E) ratio is increased</li>
<li>Blast percentage: &lt;10% in chronic phase, 10-19% in accelerated phase, and ≥20% in blast phase</li>
</ul>
</li>
<li>Cytogenetic Analysis:
<ul>
<li>Philadelphia chromosome (Ph chromosome): t(9;22)(q34.1;q11.2)</li>
</ul>
</li>
<li>Molecular Testing:
<ul>
<li>BCR-ABL1 Fusion Gene: Detected by PCR or FISH (fluorescence in situ hybridization)</li>
</ul>
</li>
</ul>
</li>
<li>
<strong>Treatment:</strong>
<ul>
<li>Tyrosine Kinase Inhibitors (TKIs):
<ul>
<li>Imatinib, dasatinib, nilotinib, bosutinib, ponatinib</li>
<li>Target the BCR-ABL1 tyrosine kinase activity, leading to apoptosis of leukemic cells</li>
<li>Highly effective in achieving and maintaining remission in most patients with chronic phase CML</li>
</ul>
</li>
<li>Hematopoietic Stem Cell Transplantation (HSCT):
<ul>
<li>Potentially curative option</li>
<li>Typically reserved for patients who fail TKI therapy or who are in accelerated or blast phase</li>
</ul>
</li>
<li>Interferon-alpha:
<ul>
<li>An older treatment option that is now less commonly used</li>
</ul>
</li>
</ul>
</li>
</ul>
</div>
<div id="polycythemia-vera-pv" class="section level2 unnumbered">
<h2>
<strong>Polycythemia Vera (PV)</strong><a class="anchor" aria-label="anchor" href="#polycythemia-vera-pv"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Definition:</strong> A myeloproliferative neoplasm characterized by increased production of red blood cells (erythrocytosis), often accompanied by increased production of white blood cells and platelets</li>
<li>
<strong>Diagnostic Criteria:</strong>
<ul>
<li>Elevated hemoglobin and hematocrit</li>
<li>Presence of the JAK2 V617F mutation (or other <em>JAK2</em> exon 12 mutation)</li>
<li>Bone marrow showing erythroid, granulocytic, and megakaryocytic proliferation</li>
</ul>
</li>
<li>
<strong>Pathophysiology:</strong>
<ul>
<li>
<em>JAK2 Mutation:</em> A mutation in the <em>JAK2</em> gene (Janus kinase 2), most commonly the V617F mutation
<ul>
<li>JAK2 is a tyrosine kinase involved in signal transduction for several growth factors, including erythropoietin (EPO)</li>
<li>The <em>JAK2</em> mutation leads to constitutive activation of the EPO receptor signaling pathway, resulting in uncontrolled RBC production, independent of EPO levels</li>
</ul>
</li>
<li>
<em>Erythroid Progenitor Hypersensitivity:</em> Erythroid progenitors become hypersensitive to growth factors</li>
</ul>
</li>
<li>
<strong>Clinical Features:</strong>
<ul>
<li>Elevated red cell mass is what causes:
<ul>
<li>Headache</li>
<li>Dizziness</li>
<li>Fatigue</li>
<li>Blurred Vision</li>
<li>Pruritus (itching, especially after a warm bath)</li>
<li>Erythromelalgia (burning pain and redness in the extremities)</li>
<li>Thrombosis: Increased risk of blood clots (stroke, heart attack, pulmonary embolism, DVT)</li>
<li>Bleeding: Paradoxically, some patients may experience bleeding due to abnormal platelet function</li>
<li>Splenomegaly: Enlarged spleen</li>
</ul>
</li>
</ul>
</li>
<li>
<strong>Laboratory Findings:</strong>
<ul>
<li>CBC:
<ul>
<li>Elevated HGB and HCT</li>
<li>Elevated RBC count</li>
<li>WBC count: May be normal or elevated</li>
<li>Platelet count: May be normal or elevated</li>
</ul>
</li>
<li>Peripheral Blood Smear:
<ul>
<li>May show erythrocytosis (increased RBCs)</li>
<li>May see some granulocytosis and thrombocytosis</li>
</ul>
</li>
<li>Serum Erythropoietin (EPO) Level:
<ul>
<li>Low or Normal</li>
</ul>
</li>
<li>JAK2 Mutation Analysis:
<ul>
<li>Positive for <em>JAK2</em> V617F mutation (or other <em>JAK2</em> mutation)</li>
</ul>
</li>
<li>Bone Marrow Examination (not always required):
<ul>
<li>Hypercellular marrow with increased erythroid, granulocytic, and megakaryocytic lineages</li>
</ul>
</li>
</ul>
</li>
<li>
<strong>Treatment:</strong>
<ul>
<li>Phlebotomy:
<ul>
<li>To reduce HCT to &lt;45%</li>
<li>Mainstay of therapy</li>
</ul>
</li>
<li>Low-Dose Aspirin:
<ul>
<li>To reduce the risk of thrombosis</li>
</ul>
</li>
<li>Cytoreductive Therapy:
<ul>
<li>Hydroxyurea: To suppress bone marrow proliferation</li>
<li>Ruxolitinib: A JAK2 inhibitor used in patients who are resistant to or intolerant of hydroxyurea</li>
</ul>
</li>
<li>Interferon-alpha:
<ul>
<li>May be used in younger patients or pregnant women</li>
</ul>
</li>
</ul>
</li>
</ul>
</div>
<div id="essential-thrombocythemia-et" class="section level2 unnumbered">
<h2>
<strong>Essential Thrombocythemia (ET)</strong><a class="anchor" aria-label="anchor" href="#essential-thrombocythemia-et"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Definition:</strong> A myeloproliferative neoplasm characterized by sustained thrombocytosis (elevated platelet count)</li>
<li>
<strong>Diagnostic Criteria:</strong>
<ul>
<li>Sustained Platelet Count ≥450 x 10^9/L</li>
<li>Bone Marrow Showing Increased Numbers of Megakaryocytes</li>
<li>Exclusion of Other MPNs: Absence of criteria for PV, PMF, or CML</li>
<li>Presence of a Clonal Marker (e.g., JAK2, CALR, or MPL mutation) or Evidence of Clonal Hematopoiesis in the Absence of Other Causes of Thrombocytosis</li>
</ul>
</li>
<li>
<strong>Pathophysiology:</strong>
<ul>
<li>Mutations in <em>JAK2</em>, <em>CALR</em>, or <em>MPL</em> genes lead to increased megakaryocyte proliferation and platelet production
<ul>
<li>
<em>JAK2</em> mutation (Janus kinase 2): Affects signal transduction</li>
<li>
<em>CALR</em> mutation (calreticulin): Affects protein folding and calcium signaling</li>
<li>
<em>MPL</em> mutation (thrombopoietin receptor): Affects thrombopoietin signaling</li>
</ul>
</li>
</ul>
</li>
<li>
<strong>Clinical Features:</strong>
<ul>
<li>Often asymptomatic</li>
<li>Thrombosis: Increased risk of blood clots (stroke, heart attack, DVT, pulmonary embolism)</li>
<li>Bleeding: Paradoxically, some patients may experience bleeding due to abnormal platelet function</li>
<li>Erythromelalgia: Burning pain and redness in the extremities</li>
<li>Splenomegaly: Enlarged spleen (less common than in PV or PMF)</li>
</ul>
</li>
<li>
<strong>Laboratory Findings:</strong>
<ul>
<li>CBC:
<ul>
<li>Elevated platelet count (≥450 x 10^9/L)</li>
<li>WBC count: May be normal or slightly elevated</li>
<li>RBC count: Usually normal</li>
</ul>
</li>
<li>Peripheral Blood Smear:
<ul>
<li>Thrombocytosis: Increased number of platelets</li>
<li>Large platelets (megathrombocytes)</li>
<li>Abnormal platelet morphology (e.g., hypogranular platelets)</li>
</ul>
</li>
<li>Bone Marrow Examination (not always required):
<ul>
<li>Increased numbers of megakaryocytes with abnormal morphology</li>
</ul>
</li>
<li>Molecular Testing:
<ul>
<li>Positive for <em>JAK2</em>, <em>CALR</em>, or <em>MPL</em> mutation (in most cases)</li>
</ul>
</li>
</ul>
</li>
<li>
<strong>Treatment:</strong>
<ul>
<li>Low-Dose Aspirin:
<ul>
<li>To reduce the risk of thrombosis</li>
</ul>
</li>
<li>Cytoreductive Therapy:
<ul>
<li>Hydroxyurea: To lower the platelet count</li>
<li>Anagrelide: Inhibits platelet production</li>
<li>Interferon-alpha: May be used in younger patients or pregnant women</li>
</ul>
</li>
</ul>
</li>
</ul>
</div>
<div id="primary-myelofibrosis-pmf" class="section level2 unnumbered">
<h2>
<strong>Primary Myelofibrosis (PMF)</strong><a class="anchor" aria-label="anchor" href="#primary-myelofibrosis-pmf"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Definition:</strong> A myeloproliferative neoplasm characterized by progressive bone marrow fibrosis (scarring), splenomegaly, and extramedullary hematopoiesis</li>
<li>
<strong>Diagnostic Criteria:</strong>
<ul>
<li>Megakaryocyte proliferation and dysplasia in the bone marrow</li>
<li>Reticulin and/or collagen fibrosis</li>
<li>Exclusion of Other MPNs: Absence of criteria for PV, ET, or CML</li>
<li>Presence of a Clonal Marker (e.g., JAK2, CALR, or MPL mutation) or Evidence of Clonal Hematopoiesis in the Absence of Other Causes of Myelofibrosis</li>
</ul>
</li>
<li>
<strong>Pathophysiology:</strong>
<ul>
<li>Mutations in <em>JAK2</em>, <em>CALR</em>, or <em>MPL</em> genes lead to:
<ul>
<li>Abnormal megakaryocyte proliferation and activation</li>
<li>Release of cytokines (e.g., TGF-β, PDGF, VEGF) that stimulate fibroblast proliferation and collagen deposition in the bone marrow</li>
</ul>
</li>
<li>Progressive bone marrow fibrosis impairs normal hematopoiesis, leading to:
<ul>
<li>Cytopenias (anemia, thrombocytopenia)</li>
<li>Extramedullary hematopoiesis (blood cell production in the spleen, liver, and other organs)</li>
</ul>
</li>
</ul>
</li>
<li>
<strong>Clinical Features:</strong>
<ul>
<li>Anemia: Fatigue, weakness</li>
<li>Splenomegaly: Abdominal discomfort, early satiety</li>
<li>Constitutional Symptoms: Fatigue, weight loss, night sweats, fever</li>
<li>Bone Pain</li>
<li>Thrombosis and Bleeding: Due to abnormal platelet function</li>
</ul>
</li>
<li>
<strong>Laboratory Findings:</strong>
<ul>
<li>CBC:
<ul>
<li>Anemia (usually present)</li>
<li>Thrombocytopenia or thrombocytosis (variable)</li>
<li>Leukoerythroblastosis: Presence of immature granulocytes and nucleated RBCs in the peripheral blood</li>
</ul>
</li>
<li>Peripheral Blood Smear:
<ul>
<li>Teardrop cells (dacrocytes): Abnormally shaped RBCs that are characteristic of PMF</li>
<li>Leukoerythroblastosis: Immature granulocytes and nucleated RBCs</li>
<li>Large, abnormal platelets</li>
</ul>
</li>
<li>Bone Marrow Aspiration and Biopsy:
<ul>
<li>Hypercellular marrow (early stages)</li>
<li>Increased megakaryocytes with abnormal morphology</li>
<li>Reticulin and/or collagen fibrosis (graded on a scale of 0-3)</li>
</ul>
</li>
<li>Molecular Testing:
<ul>
<li>Positive for <em>JAK2</em>, <em>CALR</em>, or <em>MPL</em> mutation (in most cases)</li>
</ul>
</li>
</ul>
</li>
<li>
<strong>Treatment:</strong>
<ul>
<li>Supportive Care:
<ul>
<li>Transfusions to manage anemia and thrombocytopenia</li>
<li>Ruxolitinib: A JAK2 inhibitor that reduces spleen size, improves constitutional symptoms, and may prolong survival</li>
<li>Danazol or thalidomide: May improve anemia or thrombocytopenia</li>
<li>Hydroxyurea: To manage thrombocytosis or leukocytosis</li>
</ul>
</li>
<li>Splenectomy: May be considered for symptomatic splenomegaly or refractory cytopenias, but carries significant risks</li>
<li>Hematopoietic Stem Cell Transplantation (HSCT):
<ul>
<li>The only potentially curative option</li>
<li>Reserved for younger patients with high-risk disease</li>
</ul>
</li>
</ul>
</li>
</ul>
</div>
<div id="key-terms-28" class="section level2 unnumbered">
<h2>
<strong>Key Terms</strong><a class="anchor" aria-label="anchor" href="#key-terms-28"><i class="fas fa-link"></i></a>
</h2>
<ul>
<li>
<strong>Myeloproliferative Neoplasm (MPN):</strong> A clonal hematopoietic stem cell disorder with increased production of myeloid cells</li>
<li>
<strong>Chronic Myeloid Leukemia (CML):</strong> MPN with the BCR-ABL1 fusion gene</li>
<li>
<strong>Polycythemia Vera (PV):</strong> MPN with increased red blood cell production; often associated with JAK2 V617F mutation</li>
<li>
<strong>Essential Thrombocythemia (ET):</strong> MPN with increased platelet production; associated with JAK2, CALR, or MPL mutations</li>
<li>
<strong>Primary Myelofibrosis (PMF):</strong> MPN characterized by bone marrow fibrosis and extramedullary hematopoiesis; associated with JAK2, CALR, or MPL mutations</li>
<li>
<strong>Extramedullary Hematopoiesis:</strong> Blood cell production outside the bone marrow (e.g., in the spleen and liver)</li>
<li>
<strong>Splenomegaly:</strong> Enlargement of the spleen</li>
<li>
<strong>Thrombosis:</strong> Formation of blood clots</li>
<li>
<strong>Hepatomegaly:</strong> Enlargement of the liver</li>
<li>
<strong>Leukoerythroblastosis:</strong> Presence of immature granulocytes and nucleated RBCs in the peripheral blood</li>
<li>
<strong>Teardrop Cells (Dacrocytes):</strong> Abnormally shaped RBCs seen in primary myelofibrosis</li>
<li>
<strong>Hydroxyurea:</strong> A chemotherapeutic drug used to suppress bone marrow proliferation</li>
<li>
<strong>Ruxolitinib:</strong> A JAK2 inhibitor used to treat MPNs</li>
</ul>
</div>
</div>
<!-- Scoll to TOC element -->
<script defer>
  function scroll_to_element() {
    header_height = document.getElementsByTagName('header')[0].offsetHeight/2;
    toc_element_position = document.querySelector('.book-toc > li > a.active').offsetTop;
    document.getElementsByTagName('header')[0].scrollTo(0, toc_element_position - header_height, 'smooth');
  }
  window.onload = scroll_to_element();
</script><div class="chapter-nav">
<div class="prev"><a href="myelodysplastic.html">Myelodysplastic</a></div>
<div class="next"><a href="lymphoid-neoplasia.html">Lymphoid Neoplasia</a></div>
</div></main><div class="col-md-3 col-lg-2 d-none d-md-block sidebar sidebar-chapter">
    <nav id="toc" data-toggle="toc" aria-label="On this page"><h2>On this page</h2>
      <ul class="nav navbar-nav">
<li><a class="nav-link" href="#myeloproliferative">Myeloproliferative</a></li>
<li><a class="nav-link" href="#overview-of-myeloproliferative-neoplasms-mpns">Overview of Myeloproliferative Neoplasms (MPNs)</a></li>
<li><a class="nav-link" href="#chronic-myeloid-leukemia-cml">Chronic Myeloid Leukemia (CML)</a></li>
<li><a class="nav-link" href="#polycythemia-vera-pv">Polycythemia Vera (PV)</a></li>
<li><a class="nav-link" href="#essential-thrombocythemia-et">Essential Thrombocythemia (ET)</a></li>
<li><a class="nav-link" href="#primary-myelofibrosis-pmf">Primary Myelofibrosis (PMF)</a></li>
<li><a class="nav-link" href="#key-terms-28">Key Terms</a></li>
</ul>

      <div class="book-extra">
        <ul class="list-unstyled">
<li><a id="book-source" href="https://github.com/brettmrice/Clinical-Hematology/blob/blob/main/Rmd/02-10-leukocyte-neoplasia-myeloid-mpn.Rmd">View source <i class="fab fa-github"></i></a></li>
          <li><a id="book-edit" href="https://github.com/brettmrice/Clinical-Hematology/blob/edit/main/Rmd/02-10-leukocyte-neoplasia-myeloid-mpn.Rmd" target="_blank">Edit this page <i class="fab fa-github"></i></a></li>
        </ul>
</div>
    </nav>
</div>

</div>
</div> <!-- .container -->

<footer class="bg-primary text-light mt-5"><div class="container"><div class="row">

  <div class="col-12 col-md-6 mt-3" style="text-align: center; flex: 100%; max-width: 100%;">
    <p>Written by Brett M. Rice | Updated 2025-02-28 | Built by the <a class="text-light" href="https://bookdown.org">bookdown</a> R package</p>
  </div>

  <!--div class="col-12 col-md-6 mt-3">
    <p>Built by the <a class="text-light" href="https://bookdown.org">bookdown</a> R package</p>
  </div-->

</div></div>
</footer>
</body>
</html>
